Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB released its interim report for the first quarter of 2025, highlighting significant events and financial developments. The report underscores the company’s ongoing commitment to research and development in inflammatory diseases, which is crucial for its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation through melanocortin biology.
Average Trading Volume: 187,789
Current Market Cap: SEK888M
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.